In this patent, the authors reported that 100 μM menadione is the strongest EGFR activator, 1000 μM PK generates 1/10th of the effect of menadione, and MK-4 is ineffectual against human squamous cell carcinoma cells (A431). This evidence concerns the gene EGFR and squamous cell carcinoma.